Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM)

X
Trial Profile

Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Sirolimus (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms FREEDOM
  • Most Recent Events

    • 19 Apr 2022 Data from this trial was used predict different outcomes with CABG vs PCI for SYNTAX and BEST trials. Results assessing the ability of the 5-year major adverse cardiovascular event (MACE) model to predict treatment benefit of CABG vs PCI in the SYNTAX and BEST trials published in the Journal of the American College of Cardiology
    • 01 Nov 2018 Results published in the Journal of the American College of Cardiology
    • 17 Jan 2017 Results of post hoc secondary analysis published in the Journal of the American College of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top